How Much Does Evenity (Romosozumab) Cost in Minnesota in 2026?

Minnesota List Price and Cash-Pay Cost

The retail cash price for Evenity in Minnesota is $1,825 per month in 2026, matching the national manufacturer list price set by Amgen and UCB. Each dose consists of two prefilled syringes delivering a combined 210 mg of romosozumab by subcutaneous injection. Over the standard 12-month treatment course, that totals approximately $21,900 out of pocket if a patient pays cash without any coverage or discount.

This price has remained relatively stable since Evenity's FDA approval in April 2019. Unlike oral bisphosphonates such as generic alendronate (which costs $10 to $30 per month), romosozumab is a monoclonal antibody biologic. Biologics carry higher manufacturing costs. That price gap is substantial, but the clinical rationale for romosozumab rests on its dual mechanism: it both builds new bone and reduces bone breakdown simultaneously [1]. The ARCH trial (N=4,093) demonstrated that romosozumab followed by alendronate reduced new vertebral fractures by 48% compared with alendronate alone at 24 months [2].

Minnesota patients filling at retail pharmacies across the Twin Cities, Duluth, Rochester, and greater Minnesota will generally see the same $1,825 figure. Price variation between pharmacies is minimal for this drug because it is dispensed as a specialty medication, often through specialty pharmacy channels rather than standard retail counters.

Minnesota Medicaid Coverage for Evenity

Minnesota Medical Assistance (Medicaid) covers Evenity with prior authorization for patients diagnosed with severe osteoporosis. The PA process requires documentation of bone mineral density (BMD) results, typically a DEXA T-score of -2.5 or lower at the hip or lumbar spine, along with evidence of high fracture risk or history of osteoporotic fracture.

Prescribers must also show that the patient has either tried and failed, or has a documented contraindication to, first-line therapies such as oral bisphosphonates. This step-therapy requirement follows the American Association of Clinical Endocrinology (AACE) 2020 guidelines, which recommend anabolic agents like romosozumab for patients classified as "very high" fracture risk [3]. The Minnesota Department of Human Services Preferred Drug List specifies the conditions under which approval is granted.

Approval turnaround varies. Some providers report receiving PA decisions within 48 to 72 hours. Others experience longer delays, particularly when clinical documentation is incomplete. Patients denied coverage can file an appeal through the Minnesota fair hearing process.

For dual-eligible patients (those enrolled in both Medicare and Medicaid), Medicare Part B typically serves as the primary payer for Evenity when it is administered in a provider's office. Medicaid then covers remaining cost-sharing obligations. This distinction matters because Medicare Part B covers provider-administered injectable drugs under its medical benefit, not the pharmacy benefit [4].

Commercial Insurance Coverage in Minnesota

Most major commercial insurers operating in Minnesota, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, PreferredOne, and UnitedHealthcare, cover Evenity on their specialty pharmacy formularies. Coverage is almost always subject to prior authorization and often requires step therapy documentation.

Typical PA criteria across these plans mirror clinical guidelines:

• Confirmed postmenopausal osteoporosis with a T-score of -2.5 or below
• High fracture risk per FRAX calculation or prior fragility fracture
• Trial of, or contraindication to, at least one oral bisphosphonate
• No history of myocardial infarction or stroke within the preceding 12 months (per the FDA boxed warning)

Out-of-pocket costs for commercially insured patients depend on plan design. Patients on high-deductible health plans may face the full $1,825 monthly cost until meeting their deductible. Patients with specialty tier copays often see $100 to $500 per fill before applying manufacturer support. Plans with coinsurance structures (such as 20% to 30% on specialty drugs) can leave patients responsible for $365 to $548 per dose at list price.

The FDA-approved prescribing information for romosozumab includes a boxed warning regarding cardiovascular risk. Insurers use this boxed warning to justify strict PA requirements. A 2020 meta-analysis published in the Journal of Bone and Mineral Research found that cardiovascular signal data from the ARCH trial showed a higher incidence of serious cardiac events in the romosozumab group versus alendronate (2.5% vs. 1.9% at 12 months) [5]. Prescribers in Minnesota should expect insurers to screen for this risk factor during the authorization process.

The Amgen/UCB Savings Card: How It Works in Minnesota

Amgen and UCB jointly offer a copay savings program for commercially insured patients prescribed Evenity. The card can reduce out-of-pocket costs to as low as $0 per dose for patients who qualify. This program is available to Minnesota residents with commercial insurance. It does not apply to patients covered by Medicare, Medicaid, TRICARE, or any other government-funded program.

Eligibility requirements are straightforward. The patient must have commercial prescription drug coverage that includes Evenity, must reside in the United States, and must not be enrolled in a government insurance program. The savings card covers up to a specified annual maximum (which Amgen periodically adjusts), and any amount exceeding that cap reverts to the patient's responsibility.

To enroll, patients or their providers can visit the Evenity savings card portal online or call the support line. Activation typically takes one to two business days. The card is then applied at the specialty pharmacy during each fill. Several specialty pharmacies serving Minnesota, including Optum Specialty, Accredo, and CVS Specialty, accept the card directly.

One practical note: savings card benefits do not count toward a patient's insurance deductible or out-of-pocket maximum under most plan designs. The Endocrine Society's 2020 clinical practice guideline on pharmacological management of osteoporosis recommends that clinicians discuss cost barriers openly, as financial toxicity is a documented driver of medication non-adherence in osteoporosis treatment [6].

Compounded Romosozumab in Minnesota: Legality and Access

Compounded romosozumab is available through licensed 503A compounding pharmacies in Minnesota under federal and state pharmacy law. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions from a licensed prescriber [7].

This deserves careful context. Compounding a biologic like romosozumab is not the same as obtaining the FDA-approved product manufactured by Amgen/UCB. Compounded versions are not FDA-approved, are not subject to the same manufacturing standards as commercially produced biologics, and are not interchangeable with Evenity. The FDA has issued guidance distinguishing between 503A (patient-specific) and 503B (outsourcing facility) compounding frameworks.

Pricing from 503A pharmacies varies widely. Some facilities advertise significantly lower costs than the branded product. Patients considering this route should verify that the compounding pharmacy holds a valid Minnesota Board of Pharmacy license and confirm the source and quality of the active ingredient with their prescribing physician.

The Minnesota Board of Pharmacy regulates 503A pharmacies within the state. Patients should confirm that any compounding pharmacy they use maintains current licensure and complies with both state and federal compounding regulations.

Telehealth Prescribing of Evenity in Minnesota

Minnesota permits telehealth prescribing of Evenity. Following pandemic-era expansions of telehealth regulations, Minnesota codified many of these provisions into permanent law. Providers licensed in Minnesota can evaluate patients via synchronous video visit and issue prescriptions for specialty medications, including romosozumab.

For a drug requiring subcutaneous injection, the telehealth model works like this: the clinician conducts the initial evaluation remotely, reviews DEXA scan results and laboratory values (calcium, vitamin D, renal function), and submits the prior authorization. The medication is then either shipped to the patient's home via specialty pharmacy or sent to a local provider's office for administration. Many patients in rural Minnesota, particularly in areas distant from Mayo Clinic or Twin Cities specialty centers, benefit from this model.

The AACE 2020 guidelines support initiation of osteoporosis treatment when fracture risk assessment, BMD testing, and laboratory workup have been completed, regardless of whether the clinical encounter is in-person or remote [3]. Patients receiving Evenity should still have in-person follow-up at intervals appropriate for monitoring treatment response, including repeat DEXA scanning at 12 to 24 months per ISCD official positions [8].

Comparing Evenity to Other Osteoporosis Treatments: Cost and Efficacy

Romosozumab is not the only option for high-risk osteoporosis, and understanding relative cost matters for Minnesota patients making treatment decisions.

Generic alendronate costs roughly $10 to $30 per month. It remains the most widely prescribed first-line agent. The Fracture Intervention Trial (FIT) demonstrated that alendronate reduced hip fracture risk by 51% in women with existing vertebral fractures (N=2,027) [9]. Teriparatide (Forteo), another anabolic agent, costs approximately $3,400 per month at list price, though generic teriparatide became available in 2023 at lower cost. Abaloparatide (Tymlos) lists at roughly $2,000 per month. Denosumab (Prolia) runs about $1,600 per administration every six months.

What sets romosozumab apart is its dual mechanism as a sclerostin inhibitor. It increases bone formation markers by up to 140% while simultaneously decreasing bone resorption markers within the first month of treatment [1]. The FRAME trial (N=7,180) showed that romosozumab reduced new vertebral fractures by 73% at 12 months compared with placebo [10]. No other single agent achieves this combined anabolic and anti-resorptive effect.

"Romosozumab represents the first therapy that both stimulates bone formation and inhibits bone resorption, offering a new mechanism of action for patients with severe osteoporosis," stated the Endocrine Society's 2020 guideline [6].

For Minnesota patients with very high fracture risk, as defined by the AACE (recent fracture within 12 months, T-score below -3.0, or multiple fractures), the guideline-recommended sequence is anabolic-first therapy (romosozumab or teriparatide) followed by an anti-resorptive agent such as alendronate or denosumab [3].

Steps to Reduce Your Evenity Cost in Minnesota

Patients and providers in Minnesota have several concrete strategies to reduce the financial burden of romosozumab treatment:

1. Confirm insurance coverage early. Request a benefits investigation before the first dose. Specialty pharmacies typically perform this step as part of intake.

2. Apply for the Amgen/UCB savings card. Commercially insured patients should enroll before filling the first prescription.

3. Use specialty pharmacy networks. Insurers often require fills through a preferred specialty pharmacy. Using an out-of-network pharmacy can result in higher costs or denial.

4. Appeal PA denials. If prior authorization is denied, file a formal appeal with supporting clinical documentation. Include DEXA results, fracture history, FRAX score, and documentation of bisphosphonate trial or contraindication.

5. Explore patient assistance programs. Amgen's Safety Net Foundation provides free Evenity to eligible uninsured or underinsured patients. Income thresholds apply.

6. Ask about 503A compounding. For patients without insurance coverage and ineligible for assistance programs, licensed 503A compounding may offer a lower-cost alternative, though with the caveats noted above regarding manufacturing standards.

7. Coordinate with Medicare Part B. Patients receiving Evenity in a provider's office (buy-and-bill model) may have it covered under Medicare Part B medical benefit with 20% coinsurance after the Part B deductible.

According to the CDC's National Center for Health Statistics, approximately 12.6% of adults over age 50 have osteoporosis at the femur neck or lumbar spine, with prevalence significantly higher in women (19.6%) than men (4.4%) [11]. In Minnesota, where the aging population continues to grow, access to effective osteoporosis treatment and financial support programs has direct public health implications.

"The goal of osteoporosis treatment is to prevent fractures. Treatment decisions should consider fracture risk, drug efficacy, cost, side effects, and patient preference," noted the USPSTF 2018 recommendation statement on screening for osteoporosis [12].